The crucial role of beta-catenin in the osteoprotective effect of semaglutide in an ovariectomized rat model of osteoporosis.
semaglutide 在卵巢切除大鼠骨質疏鬆模型中對骨保護作用的關鍵角色:β-catenin 的作用。
Naunyn Schmiedebergs Arch Pharmacol 2024-09-10
Effects of glucagon‑like peptide‑1 receptor agonists on fracture healing in a rat osteoporotic model.
糖尿病樣肽-1受體激動劑對大鼠骨質疏鬆模型骨折癒合的影響。
Exp Ther Med 2023-08-11
骨質疏鬆症常見且易導致骨折,尤其老年人。GLP-1 RAs對骨骼有積極影響,但在預防骨折方面仍待研究。研究指出,GLP-1 RA 利拉魯肽治療可改善骨癒合、減少破骨細胞、增強骨強度和密度,顯示潛力成為骨質疏鬆性骨折治療。
PubMedDOI
Effect of Liraglutide on Osteoporosis in a Rat Model of Type 2 Diabetes Mellitus: A Histological, Immunohistochemical, and Biochemical Study.
Liraglutide對2型糖尿病大鼠骨質疏鬆症的影響:組織學、免疫組織化學和生化研究。
Microsc Microanal 2023-12-25
Narrative Review of Effects of Glucagon-Like Peptide-1 Receptor Agonists on Bone Health in People Living with Obesity.
肥胖患者中胰高血糖素樣肽-1受體激動劑對骨骼健康影響的敘述性回顧。
Calcif Tissue Int 2024-03-08
Once-weekly semaglutide versus placebo in adults with increased fracture risk: a randomised, double-blinded, two-centre, phase 2 trial.
一周一次的semaglutide與安慰劑在具有增加骨折風險的成年人中的比較:一項隨機、雙盲、雙中心、2期試驗。
EClinicalMedicine 2024-05-14
Role of LRP5/6/GSK-3β/β-catenin in the differences in exenatide- and insulin-promoted T2D osteogenesis and osteomodulation.
LRP5/6/GSK-3β/β-catenin 在 exenatide 和胰島素促進的 T2D 骨生成和骨調控差異中的作用。
Br J Pharmacol 2024-05-28
Glucagon-like Peptide-1 Receptor Agonists and Diabetic Osteopathy: Another Positive Effect of Incretines? A 12 Months Longitudinal Study.
胰高血糖素樣肽-1受體激動劑與糖尿病性骨病:胰高血糖素樣激素的另一個正面效應?一項為期12個月的縱向研究。
Calcif Tissue Int 2024-06-12
Liraglutide, a glucagon-like peptide-1 receptor agonist, inhibits bone loss in an animal model of osteoporosis with or without diabetes.
瑞格列酸(Liraglutide),一種類胰高血糖素-1受體激動劑,在一個具有或不具有糖尿病的骨質疏鬆動物模型中抑制骨質流失。
Front Endocrinol (Lausanne) 2024-06-13
Semaglutide Alleviates Ovary Inflammation via the AMPK/SIRT1/NF‑κB Signaling Pathway in Polycystic Ovary Syndrome Mice.
Semaglutide 透過 AMPK/SIRT1/NF‑κB 信號通路減輕多囊卵巢症候群小鼠的卵巢炎症。
Drug Des Devel Ther 2024-09-09